H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Microbiology D-index 41 Citations 7,990 86 World Ranking 3272 National Ranking 1308

Research.com Recognitions

Awards & Achievements

2007 - Fellow of the American Association for the Advancement of Science (AAAS)

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Immune system
  • Gene

His primary areas of study are Internal medicine, Interleukin, Immunology, Tumor necrosis factor alpha and Endocrinology. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Hereditary angioedema. Jeffrey A. Gelfand has included themes like Platelet, In vitro and Septic shock in his Interleukin study.

The study incorporates disciplines such as Necrosis, Shock and Microbiology in addition to Septic shock. His Immunology study incorporates themes from Clindamycin, Regimen, Radioimmunoassay and Babesia. He works mostly in the field of Tumor necrosis factor alpha, limiting it down to topics relating to Peripheral blood mononuclear cell and, in certain cases, Gene expression, Complement system and Lipopolysaccharide.

His most cited work include:

  • Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. (877 citations)
  • Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever (692 citations)
  • Treatment of Hereditary Angioedema with Danazol (503 citations)

What are the main themes of his work throughout his whole career to date?

Jeffrey A. Gelfand focuses on Immunology, Internal medicine, Endocrinology, Interleukin and Immune system. Immunology connects with themes related to Molecular biology in his study. His research integrates issues of Gastroenterology and Hereditary angioedema in his study of Internal medicine.

In his works, he performs multidisciplinary study on Endocrinology and Danazol. His Interleukin research is multidisciplinary, relying on both Tumor necrosis factor alpha, In vitro, Lipopolysaccharide, Receptor and Radioimmunoassay. His Tumor necrosis factor alpha research is multidisciplinary, incorporating perspectives in Peripheral blood mononuclear cell and Shock.

He most often published in these fields:

  • Immunology (28.48%)
  • Internal medicine (22.15%)
  • Endocrinology (14.56%)

What were the highlights of his more recent work (between 2015-2021)?

  • Immune system (12.03%)
  • Antibody (9.49%)
  • Cancer research (6.96%)

In recent papers he was focusing on the following fields of study:

Jeffrey A. Gelfand mainly investigates Immune system, Antibody, Cancer research, Antimicrobial and Microbiology. His Immune system study necessitates a more in-depth grasp of Immunology. His Antibody study combines topics from a wide range of disciplines, such as Protein domain, Internal medicine, Fusion protein and Severe acute respiratory syndrome coronavirus 2.

Jeffrey A. Gelfand combines subjects such as Immunoglobulin M, Immunoassay and Seroprevalence with his study of Internal medicine. His Cancer research research is multidisciplinary, incorporating elements of Tumor microenvironment, Cancer, Immunotherapy and Combination therapy. His work in the fields of Microbiology, such as Antibiotic resistance and Neisseria gonorrhoeae, intersects with other areas such as Genotoxicity, Gonorrhea and ABL.

Between 2015 and 2021, his most popular works were:

  • Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. (80 citations)
  • Rethinking the role of hydroxychloroquine in the treatment of COVID-19. (65 citations)
  • Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. (37 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Immune system
  • Antibody

Jeffrey A. Gelfand mostly deals with Escherichia coli, Antibody, Tumor microenvironment, Cancer research and CXCR4 antagonist. His Escherichia coli research also works with subjects such as

  • Antimicrobial which connect with Tetracycline antibiotics, Pharmacology, Photodynamic therapy and Urinary system,
  • Antibiotics which intersects with area such as Catheter,
  • Doxycycline, which have a strong connection to Tetracycline, Iodide, Singlet oxygen, Photochemistry and Hydrogen peroxide. His Antibody research integrates issues from Prevalence, Internal medicine and Severe acute respiratory syndrome coronavirus 2.

Jeffrey A. Gelfand interconnects Immunoassay and Immunoglobulin G, Immunoglobulin M in the investigation of issues within Internal medicine. His biological study spans a wide range of topics, including CD40, Immunosuppression and CD8, Immune system, Antigen. His Serology study is concerned with the larger field of Immunology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

S Okusawa;J A Gelfand;T Ikejima;R J Connolly.
Journal of Clinical Investigation (1988)

1248 Citations

Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever

J.G. Cannon;R.G. Tompkins;J.A. Gelfand;H.R. Michie.
The Journal of Infectious Diseases (1990)

984 Citations

Treatment of Hereditary Angioedema with Danazol

Jeffrey A. Gelfand;Richard J. Sherins;David W. Alling;Michael M. Frank.
The New England Journal of Medicine (1976)

781 Citations

Hereditary angioedema: the clinical syndrome and its management.

Michael M. Frank;Jeffrey A. Gelfand;John P. Atkinson.
Annals of Internal Medicine (1976)

748 Citations

Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome

Charles A. Dinarello;Jeffrey A. Gelfand;Sheldon M. Wolff.
JAMA (1993)

597 Citations

A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.

Go Wakabayashi;Jeffrey A. Gelfand;John F. Burke;Robert C. Thompson.
The FASEB Journal (1991)

535 Citations

Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli.

G Wakabayashi;J A Gelfand;W K Jung;R J Connolly.
Journal of Clinical Investigation (1991)

354 Citations

Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself

Ralf Schindler;Jeffrey A. Gelfand;Charles A. Dinarello..
Blood (1990)

309 Citations

Persistent and relapsing babesiosis in immunocompromised patients.

Peter J. Krause;Benjamin E. Gewurz;Benjamin E. Gewurz;David Hill;Francisco M. Marty.
Clinical Infectious Diseases (2008)

267 Citations

Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor.

James E. Gadek;Stephen W. Hosea;Jeffrey A. Gelfand;Maria Santaella.
The New England Journal of Medicine (1980)

248 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Jeffrey A. Gelfand

Charles A. Dinarello

Charles A. Dinarello

University of Colorado Denver

Publications: 133

Marco Cicardi

Marco Cicardi

University of Milan

Publications: 71

Michael M. Frank

Michael M. Frank

Duke University

Publications: 48

Peter J. Krause

Peter J. Krause

Yale University

Publications: 36

Jonathan A. Bernstein

Jonathan A. Bernstein

Stanford University

Publications: 27

Timothy J. Craig

Timothy J. Craig

Pennsylvania State University

Publications: 26

Stefan Endres

Stefan Endres

Ludwig-Maximilians-Universität München

Publications: 25

Mihai G. Netea

Mihai G. Netea

Radboud University Nijmegen

Publications: 24

Michael Kirschfink

Michael Kirschfink

Heidelberg University

Publications: 24

Jean-Marc Cavaillon

Jean-Marc Cavaillon

Institut Pasteur

Publications: 23

Per-Olof Hasselgren

Per-Olof Hasselgren

Beth Israel Deaconess Medical Center

Publications: 23

Marcel Levi

Marcel Levi

University College London Hospitals NHS Foundation Trust

Publications: 22

Jos W. M. van der Meer

Jos W. M. van der Meer

Radboud University Nijmegen

Publications: 20

Steven M. Opal

Steven M. Opal

Brown University

Publications: 20

Stephen F. Lowry

Stephen F. Lowry

Rutgers, The State University of New Jersey

Publications: 18

George Füst

George Füst

Semmelweis University

Publications: 18

Something went wrong. Please try again later.